Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 163

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 163
---
 CA 91942                      |     |            |        |     |            |     |   |
| Series NC Preferred |     | All Officers and Directors as a Group |     |            | 15,007 |     |            | 100 | % |

<div align='center'>123</div>

SALES OF UNREGISTERED SECURITIES

August 22, 2025 to November 12, 2025

On August 14, 2025 Regen Biopharma, Inc. (the “Company”) issued 1,000,000 common shares (“Shares”) in satisfaction of $ 22, 125 of principal convertible indebtedness and $10,325 of accrued interest on convertible indebtedness.

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.

Between September 16, 2025 and September 18, 2025 the Company issued 5,820,000 common shares (“Shares”) for consideration consisting of $58,200.

The Shares were issued pursuant to a Tier 2 Regulation A Offering. The Shares were sold directly through our management.

On October 2, 2025 the Company entered into a consulting agreement with Dr. Harry Lander (“Lander Agreement”). Under the terms and conditions of the Lander Agreement Harry Lander will assist the Company in regard to a planned Phase I Clinical Trial of HemaXellerate . The term of the Lander Agreement is from October 3, 2025 to the earlier of October 3, 2028 or successful completion of the planned Phase I Clinical Trial of HemaXellerate (“ Consulting Period”).

As consideration for services to be rendered pursuant to this Agreement Dr. Lander was paid twenty million newly issued common shares of the Company (“Compensation Shares”) subject to a vesting schedule.

The Compensation Shares may not be sold, transferred, assigned, pledged or otherwise encumbered or disposed of by Lander (“ Transfer Restriction”) except as follows:

All Compensation Shares shall vest upon successful completion of planned Phase I Clinical Trial of HemaXellerate, such Clinical Trial having been conducted with the assistance of the Consultant pursuant to the